HOME >> BIOLOGY >> NEWS
Managing maternal depression during pregnancy presents significant challenge to clinicians

PITTSBURGH, May 18 Women who take antidepressants during the final trimester of pregnancy through delivery increase the risk of "neonatal behavioral syndrome," a constellation of symptoms and behaviors largely related to drug withdrawal or side effects, University of Pittsburgh researchers conclude in a review of medical literature. Such findings reveal an additional challenge for clinical management of depression during pregnancy, Eydie Moses-Kolko, M.D., assistant professor of psychiatry at the University of Pittsburgh School of Medicine, and her colleagues write in the May 18 issue of the Journal of the American Medical Association.

"The FDA and drug manufacturers recently agreed to label revisions for antidepressants known as selective serotonin reuptake inhibitors. Now the label for these drugs includes information about potential adverse effects to newborns if the drug is taken late in pregnancy," said Dr. Moses-Kolko, who also is on staff with the Women's Behavioral HealthCARE program of the Western Psychiatric Institute and Clinic of the University of Pittsburgh Medical Center. "Late exposure was associated with increased risk for a range of complications including jitteriness, stiffened muscle tone, irritability, respiratory distress and feeding problems."

While most cases of neonatal behavioral syndrome are mild and generally resolve in about two weeks, a number are severe enough to require neonatal intensive-care unit (NICU) hospitalization.

"Newborns exposed to antidepressants late in pregnancy had more than twice the risk of admission to a special-care nursery as those exposed only early in pregnancy," Dr. Moses-Kolko said, adding that late-exposed newborns also had twice the risk of respiratory complications some critical. "Respiratory distress ranged from congestion and rapid breathing to extreme danger requiring oxygen therapy and even mechanical ventilation," she said. "A severe syndrome with dehydration, mechanical ventila
'"/>


17-May-2005


Page: 1 2 3

Related biology news :

1. Endogenous cannabinoids linked to fetal brain damage imposed by maternal cannabis use
2. A few more minutes of maternal attachment may reduce anemia in children
3. Childrens Hospital Oaklands new maternal diet study
4. Childrens Hospital and Research Center-Oakland presents a new maternal diet study
5. Call for global action over continued huge burden of maternal deaths in poor countries
6. Preconception care crucial to improving maternal and infant health
7. Zebra finch males prefer females with exaggerated maternal traits
8. Infant bone growth and maternal vitamin D levels during pregnancy influence future fracture risk
9. Sex chromosome genes influence aggression andmaternal behavior, say UVa researchers
10. ASU researchers find link between social behavior, maternal traits in bees
11. Ingestion of afterbirth appears to promote maternal behavior in mammals

Post Your Comments:
(Date:7/24/2014)... - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) ... long-term, randomized, active control Phase 3 study of Zerenex ... binder, for the treatment of hyperphosphatemia in patients with ... (PhosphatE binding and iRon delivery with FErric CiTrate in ... of the American Society of Nephrology ( JASN ...
(Date:7/24/2014)... YORK, NY (July 24, 2014) Scientists at ... Institute are one step closer to creating a ... a patient,s own cells. , For the ... (iPS) cells lines from skin samples of patients ... developed an accelerated protocol to induce these stem ...
(Date:7/24/2014)... have decreased by 45% on average over a 35 ... a study on the impact of humans on declining ... benefits invertebrates such as insects, spiders, crustaceans, slugs and ... pest control for crops, decomposition for nutrient cycling, water ... Science and led by UCL, Stanford and ...
Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3
(Date:7/25/2014)... A new study by researchers from the University ... tiny nanosystems function, unlocking the potential to create ... study, which has been published in the prestigious ... a novel laser technique to examine in rich ... a small cluster containing an acetylene molecule and ...
(Date:7/25/2014)... 25, 2014 Lawrence Livermore scientists Charles ... Reuters list of " The World's Most Influential Scientific ... the 3,000 researchers who were identified by analyzing citation ... who published the highest-impact work (2002-2012 and 2012-2013). The ... combustion modeling . , "This recognition is a ...
(Date:7/24/2014)... July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the ... randomized, active control Phase 3 study of Zerenex (ferric ... for the treatment of hyperphosphatemia in patients with end-stage ... binding and iRon delivery with FErric CiTrate in EsrD) ... the American Society of Nephrology ( JASN ). ...
(Date:7/24/2014)...  ECC West Africa, LLC (ECC) signed a contract ... College Hospital (UCH) Ibadan Board of Management for the ... construct, and operate and maintain a new, state-of-the-art Cancer ... the first of the 4-phase project, ECC will conduct ... UCH Ibadan intends to finance and develop the Cancer ...
Breaking Biology Technology:Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 3Scientists Burst onto Influential List for Combustion Research 2Scientists Burst onto Influential List for Combustion Research 3Scientists Burst onto Influential List for Combustion Research 4Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2
Cached News: